-
Nimotuzumab (h-R3,
BIOMAb EGFR, Biocon, India; TheraCIM,
CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher,
Center of
Molecular Immunology...
-
India include INSUGEN (rh-insulin),
BASALOG (Glargine),
BIOMAb EGFR (
Nimotuzumab),
BLISTO (Glimepiride + Metformin),
CANMAb (Trastuzumab),
Evertor (Everolimus)...
- The
company also
advanced other clinical-stage products,
including Nimotuzumab, an EGFR-targeting
monoclonal antibody, and CYT997, a
vascular disrupting...
- HER2/neu
overexpression targets the HER2/neu (erbB2)
receptor humanized nimotuzumab approved in
squamous cell carcinomas,
Glioma clinical trials for other...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
-
Depatuxizumab mafodotin ****uximab
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
